



# Synthesis, Fe(II)-induced degradation, and antimalarial activities of 1,5-diaryl-6,7-dioxabicyclo[3.2.2]nonanes: direct evidence for nucleophilic *O*-1,2-aryl shifts

Masaki Kamata,<sup>a,\*</sup> Motoko Ohta,<sup>a</sup> Ken-ichi Komatsu,<sup>a</sup> Hye-Sook Kim<sup>b</sup> and Yusuke Wataya<sup>b</sup>

<sup>a</sup>Department of Chemistry, Faculty of Education and Human Science, Niigata University, Ikarashi, Niigata 950-2181, Japan

<sup>b</sup>Faculty of Pharmaceutical Sciences, Okayama University, Tsushima, Okayama 700-8530, Japan


Received 21 December 2001; revised 16 January 2002; accepted 18 January 2002

**Abstract**—1,5-Diaryl-6,7-dioxabicyclo[3.2.2]nonanes **1a–d** (**1a**: Ar = *p*-FC<sub>6</sub>H<sub>4</sub>, **1b**: Ar = Ph, **1c**: Ar = *p*-MeC<sub>6</sub>H<sub>4</sub>, **1d**: Ar = *p*-MeOC<sub>6</sub>H<sub>4</sub>) were prepared by a modified method of photo-electron transfer oxygenation, and the reactions of **1** with FeBr<sub>2</sub> were investigated under various conditions. The Fe(II)-induced degradation of **1** afforded various rearrangement products and fragmentation products through competitive single electron transfer (SET) and Lewis acid pathways. Direct evidence for the *O*-1,2-aryl shift was obtained by the isolation of rearrangement products, 1-aryloxy-5-aryl-8-oxabicyclo[3.2.1]octanes **8**. The degradation mechanism was proposed and the *in vitro* antimalarial activities were also evaluated. © 2002 Elsevier Science Ltd. All rights reserved.

The discovery of non-alkaloidal antimalarial endoperoxides such as artemisinin and related compounds has stimulated synthetic and mechanistic studies on antimalarial cyclic peroxides.<sup>1–14</sup> In particular, considerable efforts have been devoted to mechanistic studies for the Fe(II)-induced degradation of cyclic peroxides to clarify potent antimalarial intermediates.<sup>15–17</sup> Posner reported that structurally simple and easily prepared 1,5-diaryl-6,7-dioxabicyclo[3.2.2]nonanes **1b** (Ar = Ph) and **1d** (Ar = *p*-MeOC<sub>6</sub>H<sub>4</sub>) are potent antimalarials.<sup>6,7</sup> They also demonstrated that the reaction of 1,5-diphenyl-substituted cyclic peroxide **1b** with FeBr<sub>2</sub> afforded various fragmentation products (**3b**, **6b**, and **7b**) and rearrangement products (**4b** and **5b**) (Scheme 1).<sup>6,7</sup> However, they later reported that the structural assign-

ment of **1b** was incorrect.<sup>7</sup> These results have prompted us to investigate the synthesis of variously substituted **1a–d**, the reactions with FeBr<sub>2</sub>, and the antimalarial activities since we have been studying the effects of aromatic substituents on the reactivities of the oxyl radical species generated from arylated cyclic peroxides.<sup>18–20</sup> Herein we wish to report our preliminary but novel results for the improved synthesis of **1a–d**, Fe(II)-induced degradation of **1a–d** involving direct evidence for nucleophilic *O*-1,2-aryl shifts,<sup>20</sup> and their antimalarial activities.

As for the synthesis of **1b–d**, Takahashi reported that 9,10-dicyanoanthracene (DCA)-sensitized photo-electron transfer (PET) oxygenation of the corresponding




## Scheme 1.


**Keywords:** 1,5-diaryl-6,7-dioxabicyclo[3.2.2]nonanes; cyclic peroxides; FeBr<sub>2</sub>; rearrangement; fragmentation; *O*-1,2-aryl shift; reaction mechanism; antimalarial activity.

\* Corresponding author. Tel./fax: +81-25-262-7150; e-mail: [kamata@ed.niigata-u.ac.jp](mailto:kamata@ed.niigata-u.ac.jp)

2,6-diaryl-1,6-heptadienes **2b–d** afforded **1b–d** in 0% (11%: in the presence of  $\text{Mg}(\text{ClO}_4)_2$ ), 37, 98% yields, respectively.<sup>21,22</sup> In order to improve the isolation procedures and the yields of **1a–c**, we modified the above method by using 2,4,6-triphenylpyrylium tetrafluoroborate (TPPBF<sub>4</sub>) as a sensitizer since TPPBF<sub>4</sub> has a stronger oxidizing power than DCA and can be easily separated from the reaction mixtures by column or TLC separation. As summarized in Scheme 2 and Table 1, TPPBF<sub>4</sub>-sensitized PET oxygenation of **2a–c** afforded the corresponding **1a–c** in reasonable yields (33–58%).<sup>†</sup> While



Scheme 2.



Scheme 3.

<sup>†</sup> A typical experimental procedure is as follows: An oxygen-purged acetonitrile (50 ml) solution of **2** (0.50 mmol) and sensitizer (TPPBF<sub>4</sub>: 0.05 mmol; DCA: 0.0125 mmol) was selectively irradiated ( $\lambda > 360$  nm) with a 2 kW Xe lamp. The resulting reaction mixture was concentrated and the residue was separated by TLC ( $\text{CH}_2\text{Cl}_2$ -*n*-hexane) to afford products. The cyclic peroxides **1a–d** were characterized by their spectral data and also confirmed by the comparison with reported spectral data.<sup>21,22</sup>

Selected data for **1d**: mp 185–186°C ( $\text{CH}_3\text{CN}$ ); IR (KBr,  $\text{cm}^{-1}$ ) 3080, 3040, 3020, 2990, 2960, 2940, 2880, 1615, 1587, 1518; <sup>1</sup>H NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  1.78–2.50 (m, 10H), 3.79 (s, 6H), 6.82–6.92 (m, 4H), 7.30–7.42 (m, 4H); <sup>13</sup>C NMR (50 MHz,  $\text{CDCl}_3$ )  $\delta$  21.28 (t, 1C), 29.36 (t, 2C), 40.44 (t, 2C), 55.25 (q, 2C), 82.48 (s, 2C), 113.53 (d, 4C), 125.75 (d, 4C), 138.54 (s, 2C), 158.56 (s, 2C). Anal. calcd C, 74.19; H, 7.25; requires C, 74.09; H, 7.11; MS (EI) 340 ( $\text{M}^+$ , 12%), 135 (100%).

<sup>‡</sup> A typical experimental procedure is as follows: To a solution of **1** (0.2 mmol) in dry THF or dry  $\text{CH}_2\text{Cl}_2$  (10 ml) was added  $\text{FeBr}_2$  (0.2 mmol). The mixture was stirred at 23–25°C under a nitrogen atmosphere for 4 h. The mixture was passed through silica gel short column and eluted with  $\text{CH}_2\text{Cl}_2$  to remove inorganic iron compounds. The eluent was concentrated and the residue was separated by TLC ( $\text{CH}_2\text{Cl}_2$ -*n*-hexane) to afford products. All products were characterized by their spectral data.

Selected data for **4c**: colorless oil; IR ( $\text{CHCl}_3$ ,  $\text{cm}^{-1}$ ) 3600–3300 (O–H), 3075, 3020, 2975, 2945, 2900, 1518, 1475, 1450, 1385, 1360, 1300, 1260; <sup>1</sup>H NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  1.76–2.42 (m, 9H), 2.35 (s, 3H), 2.36 (s, 3H), 3.80–3.91 (m, 1H), 7.14–7.24 (m, 4H), 7.35–7.47 (m, 4H); <sup>13</sup>C NMR (50 MHz,  $\text{CDCl}_3$ )  $\delta$  21.09 (q, 2C), 25.96 (t, 1C), 33.25 (t, 1C), 35.67 (t, 1C), 36.39 (t, 1C), 70.35 (d, 1C), 84.59 (s, 1C), 86.36 (s, 1C), 124.36 (d, 2C), 124.77 (d, 2C), 128.81 (d, 2C), 128.99 (d, 2C), 136.31 (s, 1C), 136.52 (s, 1C), 140.68 (s, 1C), 143.48 (s, 1C).

Selected data for **5d**: colorless oil; IR ( $\text{CHCl}_3$ ,  $\text{cm}^{-1}$ ) 3050, 3020, 2970, 2950, 2930, 2890, 2850, 1675 (C=O), 1603, 1580, 1512; <sup>1</sup>H NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  1.70–2.36 (m, 6H), 2.47–2.67 (m, 1H), 2.95–3.14 (m, 1H), 3.80 (s, 3H), 3.83 (s, 3H), 3.89–4.01 (m, 2H), 6.82–6.92 (m, 4H), 7.26–7.35 (m, 2H), 7.78–7.88 (m, 2H); <sup>13</sup>C NMR (50 MHz,  $\text{CDCl}_3$ )  $\delta$  25.56 (t, 1C), 33.61 (t, 1C), 36.38 (t, 1C), 39.36 (t, 1C), 55.18 (q, 1C), 55.36 (q, 1C), 67.60 (t, 1C), 85.84 (s, 1C), 113.41 (d, 2C), 113.45 (d, 2C), 126.29 (d, 2C), 129.99 (s, 1C), 130.20 (d, 2C), 138.06 (s, 1C), 158.09 (s, 1C), 163.14 (s, 1C), 199.03 (s, 1C).

Selected data for **7d**: mp 126–127.5°C ( $\text{CH}_3\text{OH}$ ); IR (KBr,  $\text{cm}^{-1}$ ) 3080, 3050, 2960, 2930, 2880, 2850, 1618, 1587, 1513; <sup>1</sup>H NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  1.62–2.12 (m, 8H), 2.25–2.40 (m, 2H), 3.80 (s, 6H), 6.84–6.93 (m, 4H), 7.37–7.47 (m, 4H); <sup>13</sup>C NMR (50 MHz,  $\text{CDCl}_3$ )  $\delta$  19.34 (t, 1C), 37.20 (t, 2C), 37.71 (t, 2C), 55.24 (q, 2C), 83.83 (s, 2C), 113.34 (d, 4C), 125.66 (d, 4C), 139.79 (s, 2C), 158.10 (s, 2C). Anal. calcd C, 77.48; H, 7.67; requires C, 77.75; H, 7.46; MS (EI) 324 ( $\text{M}^+$ , 13%), 135 (100%).

Selected data for **8d**: mp 109–110°C ( $\text{CH}_3\text{OH}$ ); IR (KBr,  $\text{cm}^{-1}$ ) 3050, 3020, 2980, 2960, 2930, 2890, 2860, 1618, 1590, 1521, 1510; <sup>1</sup>H NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  1.52–2.28 (m, 10H), 3.76 (s, 3H), 3.80 (s, 3H), 6.75–6.92 (m, 4H), 7.13–7.24 (m, 2H), 7.28–7.38 (m, 2H); <sup>13</sup>C NMR (50 MHz,  $\text{CDCl}_3$ )  $\delta$  19.60 (t, 1C), 32.44 (t, 1C), 34.07 (t, 1C), 34.90 (t, 1C), 37.53 (t, 1C), 55.22 (q, 1C), 55.46 (q, 1C), 84.19 (s, 1C), 109.51 (s, 1C), 113.40 (d, 2C), 113.92 (d, 2C), 123.31 (d, 2C), 125.37 (d, 2C), 138.96 (s, 1C), 147.95 (s, 1C), 155.64 (s, 1C), 158.21 (s, 1C). Anal. calcd C, 74.02; H, 7.12; requires C, 74.09; H, 7.11; MS (EI) 340 ( $\text{M}^+$ , 21%), 217 (100%).

Selected data for the mixture of **9d** and **10d**: pale yellow oil; IR (neat,  $\text{cm}^{-1}$ ) 3050, 2960, 2950, 2920, 2850, 1702 (C=O), 1608, 1573, 1512; <sup>1</sup>H NMR (200 MHz,  $\text{CDCl}_3$ ) for **9d**:  $\delta$  2.02–2.20 (m, 2H), 2.60–2.85 (m, 4H), 3.32 (d, 2H,  $J=6.3$  Hz), 3.81 (s, 3H), 5.79 (t, 1H,  $J=6.3$  Hz), 6.82–6.92 (m, 2H), 7.22–7.33 (m, 2H); <sup>1</sup>H NMR (200 MHz,  $\text{CDCl}_3$ ) for **10d**:  $\delta$  2.43–2.56 (m, 2H), 2.60–2.85 (m, 6H), 3.81 (s, 3H), 6.03 (t, 1H,  $J=5.8$  Hz), 6.82–6.92 (m, 2H), 7.22–7.33 (m, 2H).

the DCA-sensitized PET oxygenation of **2d** produced **1d** in good yield (87%) as reported in the literature,<sup>21,22</sup> the TPPBF<sub>4</sub>-sensitized PET oxygenation of **2d** resulted in the decomposition of **1d**. These results indicate that the choice of a suitable sensitizer is essential for the PET oxygenation of **2**. Thus, TPPBF<sub>4</sub> is suitable for the less electron-donating substrates such as **2a–c** whereas DCA is suitable for the more electron-donating substrate such as **2d**.

In order to clarify the reactivities of the oxyl radical species generated from **1a–d**, the reactions of **1a–d** with  $\text{FeBr}_2$  were performed (Scheme 3). When 1,5-di(*p*-fluorophenyl)-substituted cyclic peroxide **1a** (0.2 mmol) was treated with 1 equiv. of  $\text{FeBr}_2$  in dry THF (10 ml) under nitrogen (4 h), 2-hydroxy-1,5-di(*p*-fluorophenyl)-8-oxabicyclo[3.2.1]octane **4a** (15%), 1-(*p*-fluorophenyl)-3-(2-(*p*-fluorophenyl)tetrahydrofuran-2-yl)propan-1-one **5a** (22%), 1,5-di(*p*-fluorophenyl)-pentan-1,5-dione **6a** (12%), and 1,5-di(*p*-fluorophenyl)-8-oxabicyclo[3.2.1]octane **7a** (33%) were obtained (run 1 in Table 2).<sup>‡</sup>

**Table 1.** PET oxygenation of 2,6-diaryl-1,6-heptadienes **2**<sup>a</sup>

Run	Substrate	Sensitizer <sup>b</sup>	Irradiation time (min)	Yield of <b>1</b> (%) <sup>c</sup>
1	<b>2a</b>	TPPBF <sub>4</sub>	50	33
2	<b>2b</b>	TPPBF <sub>4</sub>	65	44
3	<b>2c</b>	TPPBF <sub>4</sub>	20	58
4	<b>2d</b>	DCA	15	87

<sup>a</sup> **2**=0.5 mmol; CH<sub>3</sub>CN=50 ml; irradiated by a 2 kW Xe lamp ( $\lambda$ >360 nm).

<sup>b</sup> TPPBF<sub>4</sub>=0.05 mmol; DCA=0.0125 mmol.

<sup>c</sup> Isolated yield by silica gel TLC.

No diol **3a** was obtained.<sup>6</sup> When **1b** and **1c** were treated with FeBr<sub>2</sub>, similar product distributions were observed (runs 2 and 3). Interestingly, a new type of product, 1-(*p*-methoxyphenyl)oxy-5-(*p*-methoxyphenyl)-8-oxabicyclo[3.2.1]octane **8d** (11%) was obtained besides **4d–7d** when 1,5-di(*p*-methoxyphenyl)-substituted **1d** was treated with FeBr<sub>2</sub> (run 4). On the other hand, **8a–c** (11%, 8%, 86%) were produced from **1a–c**, respectively in the reactions of **1a–c** with FeBr<sub>2</sub> in dry CH<sub>2</sub>Cl<sub>2</sub> (runs 5–7). On the contrary, 4-(*p*-methoxyphenyl)cyclohept-3-en-1-one **9d** and 4-(*p*-methoxyphenyl)cyclohept-4-en-1-one **10d** (**9d+10d**=74%) were newly produced accompanied with *p*-methoxyphenol **11d** (65%) when **1d** was treated with FeBr<sub>2</sub> in dry CH<sub>2</sub>Cl<sub>2</sub> (run 8). Interestingly, a catalytic amount of FeBr<sub>2</sub> (0.5 equiv.) also promoted the O–O bond cleavage reactions of **1b** and **1d** (runs 9 and 10). A control experiment in CH<sub>2</sub>Cl<sub>2</sub> demonstrated that **8d** was decomposed by a catalytic amount of FeBr<sub>2</sub> to afford **9d**, **10d**, and **11d** quantitatively (Lewis acid-catalyzed fragmentation).<sup>20</sup> Addition of an electron-donating compound such as 1,2,4,5-tetramethoxybenzene (TMB) slightly suppressed the fragmentation of **8d** (run 11).

On the basis of the above results, we propose a plausible mechanism as shown in Scheme 4. Both in THF

and CH<sub>2</sub>Cl<sub>2</sub>, the mono-oxyl radical intermediate **A** is generated by single electron transfer (SET) from Fe(II) to **1**.<sup>6,7,20,23</sup> Four different pathways are plausible for the product formation from **A**. The first and the second pathways are the formation of **5** (path a-1: C<sub>1</sub>–C<sub>2</sub> cleavage) and **6** (path a-2: C<sub>1</sub>–C<sub>8</sub> cleavage) through C–C bond cleavage. The third is the formation of the intermediate **B** through a 1,5-hydrogen shift followed by direct epoxidation to afford the intermediate **C** (path b), which finally rearranges to **4** through an intramolecular nucleophilic cyclization. The fourth is the formation of deoxygenated product **7** through an electrophilic oxyl radical 1,5-substitution accompanied with elimination of the Fe(IV)=O species (path c).<sup>20</sup> In CH<sub>2</sub>Cl<sub>2</sub>, Fe(II) also acts as a Lewis acid that generates the complex of **1** with Fe(II) (**1-Fe(II)**). **1-Fe(II)** undergoes a nucleophilic *O*-1,2-aryl shift to generate the intermediate **D** (path d),<sup>20</sup> which is promoted by electron-donating substituents (*p*-An>*p*-Tol>Ph=*p*-FC<sub>6</sub>H<sub>4</sub>; runs 5–9). The intermediate **D** undergoes cyclization to afford the rearrangement product **8** which is direct evidence for the nucleophilic *O*-1,2-aryl shift. In the presence of the Fe(II) species (Lewis acid), **8d** easily undergoes fragmentation to afford **9d**, **10d**, and **11d**. Thus, the products **4–7** are produced through the SET pathway while **8–11** are produced through the Lewis acid pathway. THF and TMB are considered to act as a weak Lewis base, interfering with the Lewis acid pathway and/or promoting the SET pathway.

The in vitro antimalarial activities of **1a–d** against *P. falciparum* and cytotoxicities against FM-3A cells were tested to clarify the relationship between the antimalarial activities and the effects of the aromatic substituents of **1** (Table 3).<sup>12</sup> The EC<sub>50</sub> values of **1a–d** against *P. falciparum* were in the range from 2.5×10<sup>-7</sup> to 9.0×10<sup>-8</sup> M and the selectivities were fairly high (60–300), regardless of their aromatic substituents. In particular, **1b–d** can be promising lead compounds for the synthesis of new antimalarial drugs. Notably, fluoro-substi-

**Table 2.** Reactions of 1,5-diaryl-6,7-dioxabicyclo[3.2.2]nonanes **1** with FeBr<sub>2</sub><sup>a</sup>

Run	Substrate	Solvent	Additive	Yields (%) <sup>b</sup>							
				<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>8</b>	<b>9+10 (9:10)<sup>c</sup></b>	<b>11</b>
1	<b>1a</b>	THF	None	0	15	22	12	33	0	0	0
2	<b>1b</b>	THF	None	0	14	24	13	42	0	0	0
3	<b>1c</b>	THF	None	0	19	27	28	34	0	0	0
4	<b>1d</b>	THF	None	0	12	22	17	31	11	0	0
5	<b>1a</b>	CH <sub>2</sub> Cl <sub>2</sub>	None	0	11	29	30	10	11	0	0
6	<b>1b</b>	CH <sub>2</sub> Cl <sub>2</sub>	None	0	9	29	29	2	8	0	0
7	<b>1c</b>	CH <sub>2</sub> Cl <sub>2</sub>	None	0	0	8	6	0	86	0	0
8	<b>1d</b>	CH <sub>2</sub> Cl <sub>2</sub>	None	0	0	0	0	0	0	74 (44:56)	65
9	<b>1b</b>	CH <sub>2</sub> Cl <sub>2</sub>	None <sup>d</sup>	0	9	28	27	1	13	0	0
10	<b>1d</b>	CH <sub>2</sub> Cl <sub>2</sub>	None <sup>d</sup>	0	0	0	0	0	0	84 (54:46)	78
11	<b>1d</b>	CH <sub>2</sub> Cl <sub>2</sub>	TMB <sup>e</sup>	0	0	0	0	3	10	72 (54:46)	77


<sup>a</sup> **1**=0.2 mmol, FeBr<sub>2</sub>=0.2 mmol, solvent=10 ml, at 23–25°C.

<sup>b</sup> Isolated yield by silica gel TLC.

<sup>c</sup> Determined by <sup>1</sup>H NMR.

<sup>d</sup> FeBr<sub>2</sub>=0.1 mmol.

<sup>e</sup> In the presence of 1,2,4,5-tetramethoxybenzene (0.2 mmol).



Scheme 4.

**Table 3.** In vitro antimalarial activities of **1** against *P. falciparum* (FCR-3 strain) and cytotoxicities against FM3A cells<sup>a</sup>

Substrate	EC <sub>50</sub> (M)		Selectivity <sup>b</sup>
	<i>P. falciparum</i>	FM3A	
<b>1a</b>	2.5 × 10 <sup>-7</sup>	1.5 × 10 <sup>-5</sup>	60
<b>1b</b>	9.0 × 10 <sup>-8</sup> (8.9 × 10 <sup>-8</sup> ) <sup>c</sup>	2.7 × 10 <sup>-5</sup> (59%) <sup>d</sup>	> 300
<b>1c</b>	1.6 × 10 <sup>-7</sup>	1.6 × 10 <sup>-5</sup> (59%) <sup>d</sup>	> 100
<b>1d</b>	1.6 × 10 <sup>-7</sup> (6.2 × 10 <sup>-8</sup> ) <sup>c</sup>	1.6 × 10 <sup>-5</sup> (83%) <sup>d</sup>	> 100
Artemisinin	7.8 × 10 <sup>-9</sup>	1.0 × 10 <sup>-5</sup>	1280
Chloroquine	1.8 × 10 <sup>-8</sup>	3.2 × 10 <sup>-5</sup>	1780

<sup>a</sup> Ref. 12.

<sup>b</sup> Selectivity = cytotoxicity/antimalarial activity.

<sup>c</sup> IC<sub>50</sub> values against *P. falciparum* (NF54 strain), Ref. 6.

<sup>d</sup> Growth percent at the concentration indicated.

tuted **1a** did not enhance the activity or the selectivity although Posner reported such a fluorine atom effect for 1,4-diaryl-2,3-dioxabicyclo[2.2.2]octanes.<sup>9</sup> Similar antimalarial activities of **1a–d** indicate that there is no significant relationship between the antimalarial activities and the effects of the aromatic substituents of **1a–d**.

In conclusion, we have improved the synthesis of **1a–c** by using the TPPBF<sub>4</sub>-induced PET oxygenation. We have found the direct evidence (isolation of **8**) for the nucleophilic *O*-1,2-aryl shifts in the Fe(II)-induced degradation of **1**. Furthermore, we have disclosed that Fe(II) acts not only as a SET donor but also as a Lewis acid in the Fe(II)-induced *O*–*O* bond cleavage of cyclic peroxides. We are conducting further studies on the Fe(II)-induced degradation of arylated cyclic peroxides to substantiate the generality of the reaction and the relationship between the reaction intermediates and the antimalarial activities.

We are grateful to Professor Eietsu Hasegawa (Faculty of Science, Niigata University), Professor Tsutomu Miyashi and Dr. Hiroshi Ikeda (Faculty of Science, Tohoku University), Professor Yasutake Takahashi (Faculty of Engineering, Mie University), and Professor Akinori Kon-no (Faculty of Engineering, Shizuoka University) for their helpful comments and assistance.

## References

- Klayman, D. L. *Science* **1985**, 228, 1049.
- Zhou, W.-S.; Xu, X.-X. *Acc. Chem. Res.* **1994**, 27, 211.
- Haynes, R. K.; Vonwiller, S. C. *Acc. Chem. Res.* **1997**, 30, 73.
- Meshnick, S. R.; Jefford, C. W.; Posner, G. H.; Avery, M. A.; Peters, W. *Parasitol. Today* **1996**, 12, 79.

5. Vennerstrom, J. L.; Fu, H.-S.; Ellis, W. Y.; Ager, A. L., Jr.; Wood, J. K.; Andersen, S. L.; Milhouse, W. K. *J. Med. Chem.* **1992**, *35*, 3023.
6. Posner, G. H.; Wang, D.; Gonzales, L.; Tao, X.; Cumming, J. N.; Klinedinst, D.; Shapiro, T. A. *Tetrahedron Lett.* **1996**, *37*, 815.
7. Posner, G. H.; Gonzales, L.; Cumming, J. N.; Klinedinst, D.; Shapiro, T. A. *Tetrahedron* **1997**, *53*, 37.
8. Bloodworth, A. J.; Hagen, T.; Johnson, K. A.; Lenoir, I.; Moussy, C. *Tetrahedron Lett.* **1997**, *38*, 635.
9. Posner, G. H.; Tao, X.; Cumming, J. N.; Klinedinst, D.; Shapiro, T. A. *Tetrahedron Lett.* **1996**, *37*, 7225.
10. Tsuchiya, K.; Hamada, Y.; Masuyama, A.; Nojima, M.; McCullough, K. J.; Kim, H.-S.; Shibata, Y.; Wataya, Y. *Tetrahedron Lett.* **1999**, *40*, 4077.
11. McCullough, K. J.; Nonami, Y.; Masuyama, A.; Nojima, M.; Kim, H.-S.; Wataya, Y. *Tetrahedron Lett.* **1999**, *40*, 9151.
12. Kim, H.-S.; Shibata, Y.; Wataya, Y.; Tsuchiya, K.; Masuyama, A.; Nojima, M. *J. Med. Chem.* **1999**, *42*, 2604.
13. Nonami, Y.; Tokuyasu, T.; Masuyama, A.; Nojima, M.; McCullough, K. J.; Kim, H.-S.; Wataya, Y. *Tetrahedron Lett.* **2000**, *41*, 4681.
14. Jefford, C. W.; Rossier, J.-C.; Milhouse, W. K. *Heterocycles* **2000**, *52*, 1345.
15. Jefford, C. W.; Kohmoto, S.; Jaggi, D.; Timari, J.; Rossier, J. C.; Rudaz, M.; Barbuzzi, O.; Gerard, D.; Burger, U.; Kamalaprija, P.; Mareda, J.; Bernardinelli, G.; Manzanares, I.; Canfield, C. J.; Fleck, S. L.; Robinson, B. L.; Peters, W. *Helv. Chim. Acta* **1995**, *78*, 647.
16. Posner, G. H.; Cumming, J. N.; Ploypradith, P.; Oh, C. H. *J. Am. Chem. Soc.* **1995**, *117*, 5885.
17. Posner, G. H.; Park, S. B.; Gonzalez, L.; Wang, D.; Cumming, J. N.; Klinedinst, D.; Shapiro, T. A.; Bachi, M. D. *J. Am. Chem. Soc.* **1996**, *118*, 3537.
18. Kamata, M.; Nishikata, Y.; Kato, M. *J. Chem. Soc., Chem. Commun.* **1996**, 2407.
19. Kamata, M.; Tanaka, T.; Kato, M. *Tetrahedron Lett.* **1996**, *37*, 8181.
20. Kamata, M.; Kudoh, T.; Kaneko, J.; Kim, H.-S.; Wataya, Y. *Tetrahedron Lett.* **2002**, *43*, 617.
21. Takahashi, Y.; Okitsu, O.; Ando, M.; Miyashi, T. *Tetrahedron Lett.* **1994**, *35*, 3953.
22. Griesbeck, A. G.; Sadlek, O.; Polborn, K. *Liebigs Ann.* **1996**, 545.
23. Abe, M.; Inakazu, T.; Munakata, J.; Nojima, M. *J. Am. Chem. Soc.* **1999**, *121*, 6556 and references cited therein.